Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Click here to view

ASH 2023

Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A
December 12th, 2023